“Rising Adoption of Dry Powder Inhalers (DPIs)”
A significant trend propelling growth in the inhalable drugs market is the rising adoption of dry powder inhalers (DPIs). These devices offer ease of use, precise dosage delivery, and improved patient compliance compared to traditional nebulizers. DPIs eliminate the need for propellants, aligning with eco-friendly initiatives, and cater to patients with chronic respiratory conditions such as asthma and COPD. For instance, the introduction of multi-dose DPIs such as GlaxoSmithKline's Ellipta platform has enhanced treatment accessibility and convenience. In addition, the increasing prevalence of respiratory disorders worldwide and heightened awareness about advanced inhalation therapies are driving the demand for DPIs, solidifying their role in market growth.
